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ABSTRACT
Neuroblastoma (NB) with MYCN amplification is a highly aggressive and 
metastatic tumor in children. The high recurrence rate and resistance of NB cells to 
drugs urgently demands a better therapy for this disease. We have recently found that 
MYCN interacts with the lysine-specific demethylase 1 (LSD1), a histone modifier that 
participates in key aspects of gene transcription. In cancer cells, LSD1 contributes to 
the genetic reprogramming that underlies to Epithelial-Mesenchymal Transition (EMT) 
and tumor metastasis. Here, we show that LSD1 affects motility and invasiveness 
of NB cells by modulating the transcription of the metastasis suppressor NDRG1 
(N-Myc Downstream-Regulated Gene 1). At mechanistic level, we found that LSD1 
co-localizes with MYCN at the promoter region of the NDRG1 gene and inhibits its 
expression. Pharmacological inhibition of LSD1 relieves repression of NDRG1 by MYCN 
and affects motility and invasiveness of NB cells. These effects were reversed by 
overexpressing NDRG1. In NB tissues, high levels of LSD1 correlate with low levels of 
NDRG1 and reduced patients survival. Collectively, our findings elucidate a mechanism 
of how MYCN/LSD1 control motility and invasiveness of NB cells through transcription 
regulation of NDRG1 expression and suggest that pharmacological targeting of LSD1 
represents a valuable approach for NB therapy.
INTRODUCTION
Neuroblastoma (NB), a disease of the sympathetic 
nervous system, is the most common solid tumor of 
infancy. Despite significant advances in the treatment of 
pediatric cancer over the past two decades, NB remains 
a highly refractory malignancy, with less than 50% 
5-year survival rates for the majority of patients who 
are diagnosed with high-risk disease. One of the most 
powerful independent prognostic indicators for this disease 
is the amplification of the MYCN oncogene, which occurs 
at high levels in approximately 25% of NBs [1-3]. High-
risk NBs often present hematogenous metastasis indicating 
that MYCN amplification control epithelial-mesenchymal 
transition (EMT) through which NB cells lose homotypic 
adhesion and acquire migratory capacity [4]. High level 
of MYCN expression has a great impact on global gene 
expression. [5]. Despite this richness of information, the 
entire and precise network of interactions that MYCN 
establishes within cancer cells remains elusive. Recently, 
we have demonstrated that MYCN interacts with LSD1/
KDM1A, a monoamine oxidase that function as master 
epigenetic regulator in NB cell lines and that the MYCN/
LSD1 complex is involved either in activation or 
repression of MYCN target genes in NB cell lines [6]. 
Importantly, the inhibition of LSD1 activity reduces 
neuroblastoma cell viability and induces differentiation. 
These findings suggest that LSD1 inhibition may have 
strong therapeutic relevance to counteract MYCN-driven 
oncogenesis. 
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LSD1 is an amine oxidase that catalyzes lysine 
demethylation in a flavin adenine dinucleotide (FAD)-
dependent oxidative reaction. LSD1 removes mono- 
and dimethyl groups from lysine 4 (H3K4) and lysine 9 
(H3K9) of histone H3, and can also targets non-histone 
proteins such as p53, E2F1, and DNMT1 [7-9]. LSD1 was 
initially described as a cofactor of the REST/CoREST 
complex. Although LSD1 can function as a co-repressor 
of transcription factors as REST, it also has been reported 
to function as a coactivator of specific transcription 
factors by removing H3K9 methylation, suggesting that 
its substrate specificity defines its biological outcome 
[10-12]. LSD1 is overexpressed in a variety of cancers 
and tends to correlate with more aggressive cancers with 
poor prognosis. There is a large body of evidence that 
LSD1 is involved in maintaining the undifferentiated, 
malignant phenotype of neuroblastoma cells and that its 
overexpression correlates with aggressive disease, poor 
differentiation and infaust outcome [13, 14]. 
To address the functional significance of LSD1 
inhibition in NB we performed global transcriptome 
analysis (RNA-seq) in LSD1-deficient NB cells. Analysis 
of differentially expressed gene (DEG) highlighted 
the biological relevance of co-target genes indicating 
that epithelial-mesenchymal transition pathway was 
significantly affected. Among genes positively affected 
by LSD1 inhibition we focused our attention on the 
metastatic tumor suppressor gene N-myc downstream 
regulated1, NDRG1. In fact, we find that NDRG1 is 
inhibited by LSD1. NDRG1 is one of the four members of 
the human NDRG family, and its designation comes from 
its expression being repressed by MYC and MYCN [15, 
16] and its expression is negatively correlated with tumor 
progression in multiple neoplasms. NDRG1 is a potent 
metastatic suppressor that has been shown to restrain 
TGF-ß-induced EMT in prostate and colon cancer cells, 
while its reduction induces EMT [17-22]. Collectively 
these studies demonstrated that NDRG1 functions as a 
metastatic suppressor that inhibits EMT in human cancer 
a key initial step in metastasis. 
We found that LSD1 inhibition suffices to de-
repress NDRG1 expression even in the presence of 
MYCN amplification. Expression of NDRG1 suppresses 
motility and invasiveness of NB cells. In silico studies of 
neuroblastoma tumor samples revealed that low expression 
of NDRG1 was associated with poor survival. Low 
NDRG1 and high LSD1 levels were mutually exclusive in 
MYCN-amplified NB samples, corroborating the in vitro 
results. Taken together, our findings provide a previously 
unidentified model to control of EMT in NB, suggesting 
that LSD1 represents a novel and promising target for 
selective inhibition of cell migration and invasiveness in 
neuroblastoma cells. 
RESULTS
LSD1 depletion selectively affects EMT pathway
LSD1 is highly expressed in undifferentiated 
Neuroblastoma and its high expression correlates with 
adverse outcome [13, 14]. We recently showed that MYCN 
interacts with LSD1 and that the LSD1/MYCN complex 
controls transcription of tumor suppressor genes such 
as p21 and CLU [6]. Moreover LSD1 inhibition results 
in cell growth arrest of cultured NB cells. To address in 
more details the role of LSD1 function in NB cells, we 
performed global transcriptome analysis (RNA-seq) of 
Tet-21/N cells treated with tranylcypromine (TCP) a potent 
inhibitor of LSD1. In parallel, we performed RNA-seq 
from Tet-21/N cells treated with siRNA targeting LSD1 
(LSD1-KD). RNA-seq data from duplicate biological 
replicas were then analyzed for differentially expressed 
gene (DEG). Statistical analysis allows us to screen out 
661 DEGs in TCP sample (log2FC ≥ 1; FDR ≤ 0.1) and 
526 DEGs in LSD1-KD (log2FC ≥ 1; FDR ≤ 0.1). 125 
were commonly present in both treatments (Figure 1A, 
B and Supplementary Table 3). To clarify the biological 
relevance of co-target genes we used Gene set enrichment 
analysis. GSEA revealed that among top scoring pathways 
the gene set of Epithelial-Mesenchymal Transition, EMT, 
was ranked as significantly affected in both TCP and 
LSD1-KD samples (Figure 1C). We quantified expression 
levels of EMT marker genes in TCP treated or LSD1-KD 
Tet-21/N cells versus control cells by qRT-PCR. As shown 
in Figure Supplementary 1, LSD1 inhibition increased the 
levels of the epithelial markers, E-cadherin, occludin and 
desmoplakin, and reduced the expression mesenchymal 
markers, Vimentin and α-SMA, whereas no significant 
differences were detected in N-cadherin expression.
Previous studies have shown that LSD1 is indeed 
involved in the control of EMT, through interaction with 
the SNAG domain of SNAI1, a master EMT regulator 
[23, 24]. Among the several genes that were affected in 
TCP-treated and LSD1-KD cells related to EMT (SAT1, 
PLAUR, TNFRSF12A, RGS4, BDNF, MPP3, NDRG1 
and SGK1) we focused our attention on the MYCN 
regulated gene, the metastasis suppressor gene NDRG1 
(N-myc downstream regulated gene 1). NDRG1 was 
first isolated as a gene up-regulated in N-Myc knockout 
mouse embryos [25] and directly repressed by MYCN 
and c-MYC through binding to the NDRG1 core promoter 
[26]. The metastasis suppressor NDRG1 is negatively 
correlated with tumor progression of several types of 
cancer, and most importantly down-regulation of NDRG1 
expression enhances cell proliferation and invasiveness. 
In contrast, its up-regulation reduces cell proliferation and 
invasiveness [27-29]. 
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Figure 1: A. Venn diagram of the DEG present in both LSD1-knockdown (LSD1-KD) and TCP treatment. B. Gene set of regulated 
genes by TCP treatment and LSD1-KD. C. Gene set enrichment analysis (GESA) plots show enrichment of gene sets regulated by LSD1-
KD and TCP treatment. In each panel, nominal NES and false discovery rates (FDRs) are indicated. D. NDRG1 gene expression was 
analyzed by qRT-PCR, using samples prepared from Tet-21/N cells and treated with TCP or siRNA-LSD1 and siRNA-control as indicated. 
LSD1 protein level in Tet-21/N cells transfected with siRNA-LSD1 or control was determined by western blot. *, statistical significance (P 
< 0.01; Student t test). E. Western blotting of protein extracts from Tet-21/N cells prepared as described in D, using NDRG1 and phospho-
NDRG1 (Thr 346) antibodies. F. NDRG1 silencing using sh-NDRG1 in Tet-21/N cells treated with TCP or vehicle, was assayed by western 
blot. G. Western blotting of protein extract from Tet-21/N treated with vehicle, TCP or 10058-F4 for 48 hrs, using NDRG1 antibody. 
Actinin has been probed as loading control. 
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To validate the role of LSD1 in NDRG1 expression 
we inhibited LSD1 in Tet-21/N cells with TCP or siRNA-
targeted knockdown and measured NDRG1 mRNA and 
protein expression levels. We found that TCP treatment 
or LSD1 silencing stimulates NDRG1 expression 
(Figure 1D and 1E). Previously immunoblotting studies 
revealed that NDRG1 might appear as multiple protein 
bands depending from the cellular context likely due to 
different isoforms and/or post-translational modifications 
such as phosphorylation and glycosylation [27, 30, 31]. 
It has been shown that the signal cascade mTORC2/
serum glucocorticoid induced protein kinase1 (SGK1) 
phosphorylates NDRG1 at T346 and this modification is 
essential to suppress tumor growth [20, 32]. Tet-21/N cells 
treated with TCP or siLSD1 were probed with an antibody 
that specifically recognize NDRG1 phosphorylated 
at T346 demonstrating that LSD1 inhibition induces 
NDRG1 phosphorylation, Figure 1E. Finally shRNA-
targeted NDRG1 knockdown demonstrates specificity of 
NDRG1 bands (Figure 1F). To address the contribution 
of MYC and LSD1 to NDRG1 expression, Tet-21/N cells 
were treated with 10058-F4, a small molecule inhibitor 
of MYC/MAX dimerization [6] that has effect on either 
cMYC then MYCN. Following 10058-F4 treatment we 
found an increase of the 43kDa NDRG1 band, while TCP 
activates the 48kDa (Figure 1G). These findings suggest 
that inhibition of either MYCN or LSD1 de-repress 
NDRG1 expression. However, while MYCN inhibition 
activates NDRG1, LSD1-KD also induces NDRG1 
phosphorylation.
MYCN and LSD1 co-localize at NDRG1 promoter 
and repress its expression
To determine whether LSD1 is directly involved in 
transcriptional control of NDRG1 we inhibited LSD1 in 
Tet-21/N cells with TCP or with siRNA against LSD1 and 
assessed the relative binding of MYCN and LSD1 to the 
NDRG1 gene by chromatin immune-precipitation (ChIP) 
assays. The immunoprecipitated chromatin samples 
were subjected to qPCR using primers corresponding to 
the transcriptional start site (TSS) of the NDRG1 gene, 
Figure 2A. As shown in Figure 2B and 2C, MYCN and 
LSD1 were both recruited selectively at the transcriptional 
start site (TSS) of the NDRG1 gene but not at distal sites 
(-10kb), indicating that the MYCN/LSD1 complex binds 
to the NDRG1 promoter. We find also that MYCN binding 
was unaffected by TCP or LSD1 depletion implying 
that MYCN binding does not require LSD1 while, in 
contrast, LSD1 binding was reduced in TCP-treated 
and LSD1-KD samples, suggesting that the binding of 
LSD1 require the catalytic activity of the enzyme. Next, 
we monitored the histone modifications occurring at 
NDRG1 promoter (Figure 2D, 2E). Depletion of LSD1 
enhances H3-acetylation whereas it reduces the repressive 
mark H3K27me3, consistent with the induction of 
NDRG1 expression in these cells. Overall, our findings 
demonstrate that: 1) both LSD1 and MYCN bare recruited 
to the NDRG1 promoter chromatin to repress NDRG1 
expression; 2) LSD1 inhibition is sufficient to relieve 
MYCN-driven NDRG1 repression.
Effects of TCP and SP2509 inhibitors on LSD1/
MYCN-mediated regulation of NDRG1
During last years several small molecular inhibitors 
of LSD1 based on different molecular mechanisms have 
been developed [33]. SP2509 is a reversible inhibitor 
of LSD1 and differently from TCP does not target the 
catalytic activity of the enzyme. SP2509 attenuates the 
binding of LSD1 to CoREST and it has been found to 
be effective in inhibition of cultured and primary AML 
blasts [34]. To further substantiate the role of LSD1 in 
the suppression of NDRG1 we analyzed the effects of 
treatment of NB cells on NDRG1 expression by treatment 
with this different LSD1 inhibitor. As shown in Figure 3A, 
SP2509 treatment enhances NDRG1 mRNA expression 
and increases the NDRG1 48kDa protein levels in a dose 
dependent manner. Thus, both TCP and SP2509 enhance 
NDRG1 expression albeit these drugs inhibit LSD1 
through different mechanisms. Because LSD1/MYCN 
negatively controls NDRG1 transcription we assessed 
whether TCP or SP2509 may interfere with the LSD1/
MYCN interaction. To this end, HEK293T cells co-
transfected with expression vectors encoding LSD1 and 
MYCN were exposed to TCP and the complex between 
MYCN and LSD1 was analyzed by immunoprecipitation. 
As shown in Figure 3B, LSD1 and MYCN readily interact 
in the absence of TCP but their association was impaired 
in presence of the drug. This inhibitory effect of TCP is 
specific to LSD1-MYCN complex since it did not interfere 
with the interaction of MYCN with its endogenous partner 
MAX (Figure 3B). In contrast, SP2509 did not inhibit 
the interaction between LSD1 and MYCN. Also LSD1/
CoREST association was inhibited by SP2509, not by 
TCP (Figure 3C). Collectively these results demonstrate 
that LSD1 activity is necessary for the interaction with 
MYCN, not with CoREST. Thus, inhibition by TCP or 
SP2509, de-represses NDRG1 expression, albeit the two 
drugs have a marked different mode of action. 
Since SP2509 is a reversible inhibitor of LSD1, 
we tested whether re-activation of NDRG1 by SP2509 
treatment was reversible. Tet-21/N cells were treated 
with SP2509 for 48 hrs and then cells were washed, fed 
with normal medium and collected at 12, 24 and 48 hrs 
thereafter SP2509 wash out. Results in Figure 3D shows 
that NDRG1 expression decreases in a time dependent 
manner following removal of the SP2509, demonstrating 
that NDRG1 activation is directly dependent upon LSD1 
inhibition. 
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Figure 2: A. Schematic representation of the NDRG1 promoter. B. and C. MYCN and LSD1 binding to NDRG1 chromatin. Cell 
treatments are indicated at the bottom of the figure. qPCR was performed with primers for NDRG1 TSS, and -10kb. D. and E. Histone 
modifications at NDRG1 chromatin; ChIPs were carried out using the indicated antibodies and analyzed with primers encompassing the 
TSS region and -10kb from TSS. Values from three independent ChIP assays are presented along with standard deviations, n = 3. Changes 
in % input are shown normalized over IgG controls and are all statistically significant (P < 0,05; Student t test). 
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Figure 3: A. NDRG1 gene expression was determined by qRT-PCR or by western blot in Tet-21/N cells treated with SP2509 at 
different concentrations, as indicated. *, statistical significance (P < 0.01; Student t test). B. Co-Immunoprecipitation with MYCN 
antibody was performed in 293T cells co-transfected with LSD1 and MYCN expression vectors and treated with TCP, SP2509 or vehicle. 
Extract were analyzed by western blotting with MYCN, LSD1 and MAX antibodies as indicated. C. Interaction between endogenous 
LSD1 and MYCN in Tet-21/N cells, treated with TCP, SP2509 or vehicle, was assessed by co-Immunoprecipitation. Cell lysates were 
immune-precipitated with a LSD1 antibody Western blot analysis was performed on immuno-precipitated extracts with LSD1 and RCOR1 
antibodies. IgG-sample was used as negative control. D. Tet-21/N cells were treated for 48 h with SP2509 or vehicle and then released into 
fresh medium for the indicated times. Cellular extracts were prepared and stained with anti-NDRG1 and phospho-NDRG1 (Thr 346). E. 
and F. Cell extracts from SK-N-BE (2) and SH-SY5Y cells treated with SP2509 at the indicated concentrations were prepared and probed 
with NDRG1 antibody. Actinin was probed as loading control. 
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To address if LSD1 inhibition affects NDRG1 
expression in the context of MYCN amplification, 
we analyzed the effect of SP2509 in a non-amplified 
MYCN SH-SY5Y cell line. Moreover, since activation 
of NDRG1 may also occurs as result of p53 binding in 
colon cancer cell lines [35] we also used the p53 mutated, 
MYCN-amplified NB cell line SK-N-BE (2) to address 
the relative contribution of p53 in NDRG1 activation. The 
SH-SY5Y (MYCN non-amplified) and MYCN-amplified 
p53 mutated SK-N-BE (2) cells were treated with SP2509 
at different concentration for 48 hrs and western blot was 
performed using the NDRG1 antibody. Results reported 
in Figure 3E, 3F show that up regulation of the 48 kDa 
NDRG1 band is observed in both cell lines demonstrating 
that NDRG1 activation by LSD1 inhibition is not due to 
p53 activity and is not cell specific. 
Collectively our results demonstrate that 
NDRG1 expression is modulated by LSD1 and that 
pharmacological LSD1 inhibition in NB cells up-regulates 
NDRG1 expression. 
Effect of LSD1 inhibition on migration and 
invasion of NB cells
NDRG1 over-expression promotes formation of 
adherent junctions and inhibits cell migration and invasion 
in several types of tumors cells indicating that NDRG1 
inhibits the establishment of the epithelial-mesenchymal 
transition (EMT) program [18, 36]. Our findings suggest 
that LSD1 pharmacological silencing might control 
EMT in NB tumor cell lines by upregulating NDRG1 
expression. 
LSD1 was demonstrated to activate the Wnt/β-
catenin signaling pathway by down-regulating the 
pathway antagonist DKK1 in colorectal cancer cells [37]. 
In different studies NDRG1 overexpression has been 
shown to inhibit β-catenin phosphorylation inducing its 
accumulation at cell membranes [21]. We examined if 
NDRG1 activation mediated by pharmacological inhibition 
of LSD1 affected β-catenin subcellular localization. To 
this end we performed immunofluorescence to detect 
β-catenin in Tet-21/N cells untreated (Ctrl) or treated 
with SP2509. As shown in Figure 4A, SP2509 enhanced 
β-catenin accumulation on cellular membrane. A modest 
increase of β-catenin protein levels was detected in Tet-
21N and SH-SY5Y cells by immuno-blotting, Figure 4B, 
suggesting that SP2509 treatment enhanced β-catenin 
accumulation on cellular membrane. Consistent with such 
effect, expression of the β-catenin downstream target, 
Cyclin D1 was down-regulated in LSD1 inhibited cells. 
These results indicate that pharmacological treatment of 
NB cells with LSD1 inhibitor results in NDRG1 activation 
and suggest that the anti-metastatic activity of NDRG1 
in NB occurs at least in part through accumulation of 
β-catenin at cell membrane.
We then asked whether treatment with LSD1 
inhibitors and over-expression of NDRG1 might impair 
the migration and invasion of tumor NB cell lines. 
Untreated Tet-21/N (High MYCN), tetracycline-treated 
(Low MYCN) and the SH-SY5Y cells were used in 
wound-healing assays in presence or absence of TCP or 
SP2509. Both Tet-21/N (High MYCN) and SH-SY5Y 
cells filled almost completely the wounded area 24hrs 
after scratching the cell monolayer, while Tet-21/N (Low 
MYCN) showed impaired migration efficiency (Figure 5A 
and 5B). TCP or SP2509 treatment markedly suppressed 
repair of the wound area. Such inhibitory effect was 
enhanced in Low-MYCN cells suggesting that reduction 
of MYCN levels cooperates with LSD1 in blocking the 
migration of LSD1-KD cells. Next, we tested the effect of 
NDRG1 over-expression on cell invasiveness of Tet-21/N 
and SH-SY5Y cells. Both cell lines were transfected with 
a human expression vector for NDRG1, whose expression 
Figure 4: A. Tet-21/N cells were treated with SP2509 or vehicle, fixed and processed for anti-β-catenin immunofluorescence and 
DAPI staining. B. Western blot assay of protein extracts of Tet-21/N and SH-SY5Y cells treated as indicated using β-catenin and Cyclin 
D1 antibodies. α-tubulin has been probed as loading control. *, P < 0,01.
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was assayed by Western blots, Figure 5C. We determined 
that overexpression of NDRG1 recapitulates the inhibitory 
effects exerted by LSD1 inhibitors. Next, we determined 
the effect of LSD1 inhibition and NDRG1 over-expression 
on cell invasion (Figure 6). Using the trans-well migration 
assay, we showed that NDRG1 overexpression as well as 
LSD1 pharmacological inhibition in both Tet-21/N and 
SH-SY5Y cells resulted in a significant reduction ( ≥ 25%) 
of migratory capacity compared with control cells.
These findings demonstrated that pharmacological 
inhibition of LSD1 blocks migration and invasion of 
neuroblastoma cells and most importantly overexpression 
Figure 5: LSD1 inhibition reduces migration of Neurobastoma cells. A. Wound healing of Tet-21/N (High MYCN), Tetracycline-
treated Tet-21/N (Low MYCN) and B. SH-SY5Y cells treated with vehicle, TCP or SP2509. C. Wound healing was performed in Tet-21/N 
and SH-SY5Y cells 3XFlag-NDRG1 or mock transfected. Migration was assessed under treatment conditions at several time points using 
a scratch wound assay. Representative phase contrast images were shown acquired at 24hrs after scratch. Western blot shows NDRG1 
protein levels in 3xFlag-NDRG1 or mock transfected Tet-21/N and SH-SY5Y cells. Actinin was used as loading control. Graphs showing 
the results represent the mean ± SD of three independent experiments carried out in duplicate. Statistical significance P < 0,01.
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of NDRG1 recapitulate these effects. Collectively, these 
findings demonstrated that pharmacological inhibition of 
LSD1 suppresses the mobility and invasiveness of cancer 
cells through up-regulation of NDRG1.
NDRG1 expression during differentiation and in 
NB tumors
It had been shown that LSD1 expression is reduced 
following in vitro induced differentiation of neuroblastoma 
cells [14, 38]. The findings reported above indicated 
that high levels of LSD1 inversely correlate to NDRG1 
expression. To address the relative expression levels of 
MYCN, LSD1 and NDRG1 during differentiation, SK-N-
BE(2) cells were induced to differentiate by treatment with 
RA. Cell samples were collected at different time points 
after treatment and analyzed for LSD1 and NDRG1 and 
MYCN expression levels. As shown in Figure 7A, in vitro 
induced differentiation results in reduction of LSD1 and 
MYCN expression along to a concomitant up-regulation 
of NDRG1 levels. These results further confirm the 
role of LSD1 on NDRG1 expression and highlight their 
antagonism during differentiation of NB cells. Moreover 
these data strongly suggest that NDRG1 can be used as 
marker of neuroblastoma differentiation in vivo.
To further corroborate the mutually exclusive 
expression of NDRG1 and LSD1 we examined the 
relevance of NDRG1 in neuroblastoma patients. 
Independent studies have shown that low NDRG1 levels 
Figure 6: Trans-membrane migration assay of Tet-21/N and SH-SY5Y cells treated with vehicle, TCP or SP2509, or 
NDRG1-transfected. Graphs showing the results represent the mean ± SD of three independent experiments carried out in duplicate. 
*, P < 0,05.
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Figure 7: A. SK-N-BE (2) cells were treated with RA up to 9 days. LSD1, NDRG1 and MYCN protein levels were detected in 
differentiated SK-N-BE (2) cells at the indicated days by western blotting. NDRG1 expression is associated with good outcome and 
differentiated tumors. B. and C. Low NDRG1 expression is associated with negative prognosis. The number of tumors is indicated in 
parentheses. Kaplan-Meier analysis is shown, with individuals grouped by median of expression of NDRG1. Log-rank P values are shown. 
Changes in expression for LSD1 D. and NDRG1 E. in ganglioneuroblastoma (GNB), ganglioneuroma (GN) and neuroblastoma (NB). F. 
Inverse correlation between the expression values of NDRG1 and LSD1 in NB tumors (Pearson’s correlation coefficient is shown). G. Box 
plot showing differential NDRG1 expression in NB tumors without (Low) or with (High) MYCN amplification.
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are associated with worse prognosis for patients with 
breast, glioma, colorectal, esophageal squamous cell 
carcinoma, and prostate cancer [19]. More recently, it 
has been reported that low levels of NDRG1 is associated 
with poor prognosis in neuroblastoma patients [39]. In 
sharp contrast, LSD1 expression inversely correlates 
with differentiation and adverse outcome [14, 38] of 
neuroblastoma. Our in vitro findings imply that also in 
patients high LSD1 and low NDRG1 levels should be 
inversely correlated in metastatic Neuroblastomas. To 
this end we analyzed available RNAseq data of 498 NBs 
and we found that high NDRG1 expression correlates 
with better overall and event-free survival (Figure 7B 
and 7C, Mann-Whitney test, P = 3.7x10-7 and P = 8.8x10-
10). Next, we analyzed LSD1 and NDRG1 expression in 
a microarray gene expression data of 59 NBs, of which 
50 were neuroblastoma and 9 were ganglioblastoma and 
ganglioneuromas. LSD1 expression was considerably 
higher in neuroblastoma than in ganglioblastomas and 
ganglioneuromas (Figure 7D). In contrast, NDRG1 
expression was higher in well-differentiated tumors 
(Figure 7E). Thus, LSD1 and NDRG1 appear to be 
expressed in opposite fashion in NB. Accordingly, 
we found that the expression of NDRG1 is inversely 
correlated with the expression of LSD1 (Figure 7F, P = 
6.5x10-5). Finally, we determined that NDRG1 expression 
levels were appreciably lower in MYCN-amplified 
NB samples (Figure 7G). Collectively, these findings 
demonstrated that high levels of LSD1 and NDRG1 
expression are mutually exclusive in neuroblastoma, and 
the expression levels of NDRG1 are significantly lower in 
MYCN-amplified tumors.
DISCUSSION
In the current study, we demonstrated that LSD1 
in cooperation with MYCN controls cell migration and 
invasiveness of neuroblastoma cells through transcription 
regulation of the metastatic suppressor NDRG1. Our 
findings support a previously unidentified model to 
control EMT in neuroblastoma, proposing that epigenetics 
changes caused by LSD1 inhibition lead to up-regulation 
of NDRG1 thereby inducing an NDRG1-dependent 
inhibitory effect on cell migration and invasiveness of 
neuroblastoma cells
We found that in neuroblastoma cells the MYCN/
LSD1 complex binds and represses NDRG1 expression. 
Following LSD1 inhibition epigenetics changes occur 
on the chromatin region surrounding the transcriptional 
start site of NDRG1 leading to transcription activation 
of NDRG1 gene expression. In a recent study it has 
been shown that the signal cascade mTORC2/serum 
glucocorticoid induced protein kinase1 (SGK1) 
phosphorylates NDRG1 [20]. It is likely that LSD1-KD 
may also affect mTORC2/GSK1 pathway, clearly further 
investigations are required to clarify the role of LSD1 in 
the phosphorylation of NDRG1.
LSD1 inhibition suppresses motility and 
invasiveness of NB cells and ectopic over expression 
of NDRG1 phenocopy the pharmacological treatments 
with LSD1 inhibitors, suggesting that de-repression of 
NDRG1 expression plays a causative role in blocking cell 
migration and invasiveness. Moreover, lowering MYCN 
expression we observed a cooperative inhibition with TCP 
to restrain cell mobility, suggesting that MYCN and LSD1 
cooperatively control EMT.
High-risk neuroblastoma (NB) with MYCN 
amplification is a highly metastatic tumor in children. 
NB presenting with hematogenesis metastasis is one 
of the most difficult cancers to cure [1, 40]. EMT is an 
important process that contributes to tumor invasion 
and dissemination [41]. How MYC control EMT is 
largely unknown [42]. EMT process requires extensive 
reorganization of the epigenetic information of the 
cells. Previous works showed that SNAIL represses 
transcription of epithelial genes such as E-cadherin, 
by recruiting repressive chromatin-modifying factors 
including Polycomb repressive complex 2 and LSD1-
CoREST complex [41]. Our findings of targeting NDRG1 
expression through LSD1 inhibitors add new insight on 
how MYCN may control EMT. Thus, LSD1 controls EMT 
through at least two different mechanisms, as co-factors of 
SNAI1 function and in association with MYCN as a direct 
epigenetic regulator of NDRG1 expression. Previous work 
showed that blocking interactions of LSD1 with SNAI1 
blocks NB cell invasion [43]. The findings reported here 
add further support to the critical role of LSD1 in EMT 
and most importantly highlight an additional mechanism 
through which LSD1 inhibition affects cell migration and 
invasiveness of NB cancer cells. Clearly multiple signaling 
pathways cooperate in the initiation and progression of 
EMT and cooperation between different pathways likely 
occurs in a synergistic manner and in a cell-type specific 
fashion. 
Therapy for high-risk patients includes 
differentiating agents. Previous studies showed that 
NDRG1 expression is regulated by differentiation-related 
environments [19]. We determined that during RA-
mediated in vitro differentiation of NB cells the NDRG1 
protein increases during time and inversely correlates with 
LSD1 and MYCN protein expression. Thus, these data 
address that NDRG1 is a biologically important MYCN/
LSD1 target, and it is inversely expressed in relation to 
MYCN and LSD1 during NB differentiation. 
The relative expression levels of NDRG1, LSD1 
and MYCN were further analyzed in neuroblastoma 
patients. Analysis of publicly available expression data 
of large number of NBs highlighted that high NDRG1 
expression correlates with better overall and event-free 
survival. Interestingly, high levels of LSD1 and NDRG1 
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expression are mutually exclusive in neuroblastoma 
tumors and NDRG1 expression levels are significantly 
lower in MYCN-amplified NB samples. Collectively, these 
findings support and corroborate the broad significance of 
our in vitro results, and suggest that NDRG1 and LSD1 
expressions can be considered as valuable biomarkers to 
monitor NB development in humans.
In summary, our findings uncover a previously 
unidentified model in the control of EMT, suggesting 
that MYCN/LSD1 inhibition de-represses NDRG1 
expression, thereby inducing an NDRG1-dependent 
inhibitory effect on cell migration and invasiveness of 
neuroblastoma cells. These findings raise the possibility 
that improved approaches aimed to target the epigenetic 
control of NDRG1 expression may lead to development 
of novel strategies to inhibit the invasive potential of 
neuroblastoma cells.
MATERIALS AND METHODS
Cell culture and treatments
Human HEK 293T, SH-SY5Y and SHEP Tet-
21/N cells were cultured in Dulbecco’s modified Eagle’s 
Medium (DMEM) supplemented with antibiotics, 10% 
fetal calf serum. SK-N-BE (2) was cultured in 1:1 mixture 
DMEM/F-12 containing 10% FBS. All cell lines were 
incubated at 37°C in humidified atmosphere with 5% 
CO2. Tet-21/N cells are cultivated with (Low MYCN) 
or without (High MYCN) tetracycline (6 days). When 
indicated, cells were treated with TCP (1mM, Enzo Life 
Sciences), SP2509 (0,3/0,5/1 µM, Cayman Chemical 
Company) or 10054-F4 (75 µM, Sigma) for 24 or 48 
hrs. To induce differentiation in SK-N-BE (2) cells were 
exposed to 10 µM all-trans Retinoic Acid for 9 days. 
LSD1 Knock-Down
100 nM siRNA targeting LSD1 (GE Dharmacon) 
or scramble were transfected in Tet-21/N cells using 
a MicroPorator Digital Bio Technology, according to 
the recently described protocol [6]. Briefly, 2x106 cells 
were collected by trypsin/EDTA digestion, washed once 
with calcium and magnesium-free PBS and resuspended 
in 100 μl of resuspension buffer, mixed with siRNA 
or scramble and electroporatated according to the 
manufacturer’s protocol. Transfected cells were seeded in 
a 100 mm dish in antibiotic-free DMEM supplemented 
with 10% FBS. The efficiency of siRNA to knockdown 
LSD1 protein expression was assayed 48h after 
transfection by western blot.
RNA sequencing
RNA was prepared from Tet-21N cells treated 
with TCP or with siLSD1 and control untreated cells. 
RNA-seq libraries (two biological replicas for each 
sample) were generated using TruSeq RNA Sample 
Prep Kit v2 (Illumina) according to the manufacturer’s 
recommendation. All the high-throughput sequencing 
experiments were run on a NexSeq 500 (Illumina) 
sequencer at the Genomix4life S.R.L., Baronissi, Salerno, 
Italy, according to standard operating procedures. Raw 
sequences files (-fastaq files) were aligned to the human 
genome (h19 version), gene-level quantification was 
performed using R-SEM and UCSC annotation [44]. 
Subsequently, data were normalized with VOOM method 
[45] and differential expression evaluated with limma 
Bioconductor packages. Differential expressed genes 
were detected applying the following cutoff: log2 Fold 
Change ≥ 1 and FDR ≤ 0.1. RNA-seq data were deposited 
to NCBI GEO and are available under accession number 
GSE80753.
RNA extraction and qRT-PCR
RNA was extracted from NB cells using EuroGold 
Trifast (EuroClone). cDNA was generated using 
Quantitec Reverse Transcription Kit (Qiagen), according 
to manufacturer’s protocol. Quantitative analysis was 
performed using SYBR Green 2X PCR Master Mix 
(Applied Biosystem). Each sample was run in triplicate 
and normalized to the expression of housekeeping beta-
glucoronidase (GUSb) gene as previously described [6]. 
Primers are presented in Supplementary Table S1.
Protein extraction and western blot
Whole-cell extracts were obtained using buffer F (10 
mM TrisHCl pH 7.5, 150 mM NaCl, 30 mM Na4O7P2, 
50 mM NaF, 5 mM ZnCl2, 0.1 mM Na3VO4, 1% Triton, 
0.1mM PMSF). 50 μg of protein extracts were loaded 
and separated by SDS-PAGE and WB was performed 
with indicated antibodies. For NDRG1 silencing in Tet-
21/N cells, 3 µg/106 cells of shRNA plasmid (Santa Cruz) 
targeting NDRG1 was used with the protocol described 
above.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were 
performed as recently described [6]. Briefly 1x107 
cells were cross-linked using formaldehyde to a final 
concentration of 1% and reaction was stopped using 
0.125M Glycine. Cell pellet was resuspended in Cell Lysis 
Buffer and after 6000 rpm centrifugation RIPA buffer 
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were added to perform nuclei lysis. DNA shearing was 
conducted by sonication using Bioruptor (Diagenode). 
A small aliquot of sonicated material was put aside and 
remaining sample immunoprecipitated using 5 micrograms 
of ChIP-grade antibodies. Rec-sepharose Protein A or 
G beads (Invitrogen) were used to immobilize immuno-
complexes and after RNAse-A treatment (37°C 1 hour) 
reverse cross-linking were performed using Proteinase 
K (Roche) for 6 hours at 65°C. Immunoprecipitated 
DNA was purified using Phenol/Chloroform and Ethanol 
precipitation techniques. The antibodies used are listed in 
Table S2. The immunoprecipitated DNA was quantified by 
qPCR with the primer sets described in Table S1. 
Migration assays
In migration experiments, 2,5 µg/106 cells of 
3xFLAG-NDRG1 or empty vector were transiently 
transfected into Tet-21/N by electroporation, by protocol 
as described previously. For transient transfections of SH-
SY5Y, cells cultured on 100 mm dishes were transfected 
with 3xFLAG-NDRG1 plasmid or empty vector using 
Lipofectamine 2000 according to manufacturer’s protocol. 
The expression of protein was determined by western 
blot. For the wound-healing assay, NDRG1-trasfected or 
control cells were plated to confluence in a 12-well plate 
and scraped with a p200 pipet tip to create a scratch of 
the cell monolayer; when indicated cells were treated 
with TCP or SP2509 for an overnight before scratch and 
during the whole experiment. Cells were then allowed 
to fill the wounded area for 2 days and images were 
acquired using a Nikon Eclipse TE 2000-U microscope. 
Percentage of wound healing was measured as following: 
[(empty area at T0)-(empty area at 24hrs)]/(empty area at 
T0) x 100. For trans-membrane migration assay, cells were 
NDRG1-transfected or pre-treated with TCP or SP2509 
for an overnight, before plating (150000 cells/chamber) 
in free serum medium in the upper side of chambers (BD 
Falcon Cell Culture Inserts). In the wells 20% of FBS was 
used as chemo-attractant. After 24 h, non-migrating cells 
were scraped-off, whereas migrating cells were stained 
with a 20% ethanol-1% crystal violet solution for 10’, 
washed thrice with water and counted at least in ten fields 
with a 10x objective. For each assay three independent 
experiments were carried out in duplicate. 
Co-immunoprecipitation
Co-immunoprecipitation assays were performed 
using Tet-21/N and HEK 293T cells. 293T cells were 
transiently co-transfected with 3xFLAG-LSD1, 3xFLAG-
MYCN or scramble by the polyethylenimine (PEI 25 K) 
method. 1 mg of protein extract from Tet-21/N cells or 0,3 
mg from HEK 293T cells, treated with TCP, SP2509 or 
vehicle, were incubated respectively with LSD1 or MYCN 
antibody and processed as previously described [6, 46]. 
Protein interactions were assessed by immunoblotting 
using the indicated antibodies. 
Immunofluorence
For immunofluorescences assay Tet-21/N were 
seeded on coverslips and treated as indicated. Cells were 
than fixed in 4% paraformaldehyde in PBS, permeabilized 
in 0.1% Triton X-100 in PBS, pre-blocked in 2% BSA- 
3%NS-PBS for 30 min at room temperature, and then 
incubated for 1 h at 37° C with mouse anti-β-catenin. 
Primary antibodies were detected by incubation with 
Cy3-coniugated anti-mouse. Images were acquired using 
a Nikon Eclipse TE 2000-U microscope.
Gene expression data for survival analysis and 
association with neuroblastoma stages
Normalized gene expression data from RNA 
sequencing of 498 tumors were downloaded from “R2: 
Genomics Analysis and Visualization Platform” (GEO ID: 
GSE62564). To test association of gene expression levels 
with overall survival and event free survival, individual 
gene expression profiles were dichotomized by median 
split into ‘high’ or ‘low’ expression groups, and Kaplan-
Meier survival curves were plotted for each group. Long 
rank test was used to evaluate the significant difference 
between the two groups. Another set of gene expression 
data of 64 tumors (GEO ID: GSE12460) including 50 
NB, 6 ganglioneuroblastoma and 3 ganglioneuroma was 
downloaded. Mann-Whitney test was used to test the 
significant different gene expression among groups. The 
correlation between the gene expression between NDRG1 
and KDM1A was evaluated by Pearson correlation in 64 
NBs. The gene expression data for Low and High MYCN 
expression (493 samples) were generate by customized 
4x44K oligonucleotide microarrays produced by Agilent 
Technologies and analyzed as previously reported [47].
Statistical analysis
All experiments were repeated two or three times. 
Graphs representing data express mean ± SD. Statistical 
significance was obtained by unpaired, two-tailed Student 
t test. P < 0,05 was considered statistically significant.
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